Kristen Dahlgren never expected to leave her successful 25-year career as a correspondent for NBC News, let alone become part of the fabric advancing cancer medicines. The transition was not driven by professional restlessness but by something far more personal: Dahlgren was diagnosed with stage II breast cancer in 2019.
Chief External Affairs Officer
Parker Institute for Cancer Immunotherapy (PICI)
“I thought I was a lifer at NBC,” Dahlgren told Inside Precision Medicine on leaving NBC News in 2024 to advocate for accelerating the development of cancer vaccines. “I loved my job. But a cancer diagnosis changes you.” That diagnosis would eventually lead her to found the Cancer Vaccine Coalition (CVC).
Her story, however, is only half of a larger narrative. The other half belongs to Parker Institute for Cancer Immunotherapy (PICI) chief executive officer Karen Knudsen, PhD, an oncology leader and healthcare executive whose career has been defined by a single, persistent challenge: how to turn scientific discovery into real-world patient impact.
With the advent of new scientific discoveries, more investment, and increasing public and private support, cancer vaccines are entering a new phase of development, which includes this integration. The goal of these vaccines is to teach the immune system to identify and attack tumors.
Together, Dahlgren and Knudsen aim to accelerate the development and delivery of cancer vaccines, one of the most promising frontiers in cancer research. Their partnership reflects a broader shift in oncology, one that is less about isolated breakthroughs and more about building systems that can deliver those breakthroughs to patients faster.
Two paths, one problem
Before joining PICI, Knudsen had navigated the upper echelons of academic medicine and healthcare leadership. As an oncology healthcare executive for Jefferson Health, Knudsen ran one of the largest health systems in the country. She also led one of the major cancer centers in the United States, a National Cancer Institute (NCI)-designated cancer center, in a role that placed her at the intersection of science and care delivery.
CEO, Parker Institute for
Cancer Immunotherapy (PICI)
The experience exposed Knudsen to a stark reality: the greatest challenge in cancer care is not always discovery—it can be cancer care delivery. “I love science, and we are funding more of it,” Knudsen told Inside Precision Medicine. “However, I don’t think that we have a science problem in the U.S. There’s a ton of science. What we have is a translation problem.” Dahlgren arrived at the same conclusion by asking researchers what was preventing them from moving forward and finding that they often felt like they were operating in silos.
What neither woman accepted was the idea that this gap was inevitable. A systemic gap exists between research and patient care, and it is not subtle. Knudsen saw it daily in the clinic. “If you’ve ever run an oncology unit, the first thing you do … is walk the infusion center. The sense of urgency gets much higher.”
Even without new scientific breakthroughs, the system has room for improvement. “Current data indicate that we could reduce cancer mortality by 20% if everyone in the U.S. with a cancer diagnosis received guideline-concordant care,” Knudsen said. “Forget even new discoveries.”
As a patient, Dahlgren encountered a different version of the same problem: she wasn’t informed of cancer vaccines or any related clinical trials. “I did a lot of medical reporting at NBC and had just been treated at one of the top hospitals, but nobody ever mentioned [cancer vaccines] as a possibility,” said Dahlgren. “There just weren’t the clinical trials available to me. I think there is a lack of awareness.”
Dahlgren continued, “The CVC started with a conversation with some doctors who were working on cancer vaccines because, frankly, I didn’t really believe that they were real or that far along because I hadn’t heard anything about it. I think that was part of the problem. There just isn’t a large public awareness of some of the research that’s going on. Even some oncologists are unable to keep up with all the cutting-edge developments.”
Between those two perspectives lies a critical insight: innovation alone is not enough. It must be accessible, scalable, and visible. That insight is at the core of PICI’s model, originally conceived by entrepreneur Sean Parker, co-founder of Napster and the first president of Facebook. With a $250-million grant from The Parker Foundation, PICI is an attempt to redesign the entire cancer immunotherapy pipeline, from discovery to commercialization.
Unlike traditional funding bodies, PICI does not simply award grants but rather establishes research sites across the country, of which there are currently seven. “The agreements allow our investigators, irrespective of geography, to freely share data and materials, so they truly are functioning [as] one institute, multiple geographies,” said Knudsen. “The whole concept here is to advance those studies from preclinical to clinical, obtaining a clinical signal so that other investors and biopharma follow suit toward the goal of near-term patient benefit.”
Cancer vaccines, now!
When Knudsen met Dahlgren at a Milken Institute event, the alignment was immediate. Dahlgren, for her part, had already recognized that PICI was building something she could not replicate alone. “They were already doing everything I wanted to do: building a system where the ecosystem could thrive and where these discoveries could reach patients.”
That meeting led PICI to strategically integrate the CVC to accelerate the development of next-generation cancer vaccines, including personalized neoantigen therapies. “Cancer vaccines have been around, but we really are at this tipping point,” Dahlgren said, who is now at a new role within the PICI as chief external affairs officer, placing vaccines at the top of PICI’s strategic priorities. Knudsen said, “As part of the scientific priorities, vaccines rise right to the top. Cancer vaccines offer a genuine opportunity to revolutionize cancer therapies.”
Several forces have converged to create this moment: advances in genomics, improved understanding of immune biology, and new platforms for vaccine delivery. “We understand the immune system better,” Dahlgren said. “This is the time to fully support this technology and get it through trials, approved, and to patients.” Dahlgren points to emerging data from clinical studies on vaccines across multiple cancer types, she said, “You hear about the work in pancreatic cancer or glioblastoma … patients who have achieved unexpected success.”
For Knudsen, the cancer vaccines won’t just be abundant and accessible; they’ll be personalized. Early clinical results, while small, are compelling, especially for hard-to-treat solid cancers (BOX 1). Knudsen highlighted a 2025 Nature study on kidney cancer led by Catherine Wu, MD, and Toni K. Choueiri, MD. “There were zero recurrences,” said Knudsen, “and everybody in that study got the vaccine. It’s a small study with single-digit patients; I believe there were nine patients. The science is getting there.”
The implications are profound, but so are the challenges. “But then who’s going to take it to the next step in a larger clinical trial?” Knudsen asked. “Biopharma wants the clinical signal.”
That gap between early success and large-scale validation is precisely where PICI aims to operate.
Patients are ready
Part of the problem is financial. The traditional venture ecosystem is not always aligned with early-stage scientific risk. “The venture world is currently locked up due to a lack of IPOs. … They do not have dry powder available to invest capital in opportunities,” Knudsen said.
PICI’s model attempts to bypass that constraint. “We ourselves are a major investor,” Knudsen said. “We’ve put about $400 million into 17 portfolio companies. … Or we just start new companies.” Revenue generated from successful commercialization is reinvested into new research, creating a self-sustaining cycle. “That’s how the nonprofit model works.”
If there is uncertainty in the system, it does not come from patients. “We’re getting reach-outs from patients … ‘What do I need to start to think about so that I can get enrolled in a trial to prevent recurrence?’” Knudsen said. “Who wouldn’t want that?” Dahlgren echoed the urgency from personal experience. “My current course of treatment is to ‘call us when you get a headache,’ and that’s a horrible way to live.”
Cancer vaccines offer a different paradigm, one that emphasizes long-term immune protection. “Imagine if you could get a vaccine … that boosts your T-cell response. … It’s just a matter of taking care of it for the rest of your life.”
Despite growing momentum, cancer vaccines remain misunderstood. “There’s definitely a misunderstanding with the term ‘vaccine,’” Dahlgren said. Knudsen is less concerned about semantics, asserting, “I don’t know if we have a name problem. I don’t think there’s anyone who is going to say, ‘I don’t want to take a vaccine’ when facing cancer.”
Where education does matter, however, is prevention. Knudsen points to the Gardasil vaccine as a case study. “When you reframe that appropriately, as a cancer vaccine … you say actually, we have cancer vaccines that will prevent cancer.” In places like Puerto Rico, Knudsen notes that high uptake of HPV vaccination has already demonstrated what is possible. “They’ll be the first place in the U.S. where cervical cancer will no longer be a thing.”
A shared urgency
While vaccines are a major focus, they are part of a broader transformation in cancer therapy. “Immunotherapy is the same as cancer therapy,” Knudsen said. “Name a cancer modality that does not have a root in the immune system.” This shift indicates a deeper understanding of cancer as an immune-mediated disease, paving the way for more personalized treatments.
What ultimately unites Dahlgren and Knudsen is not just a belief in science but a shared sense of urgency. Dahlgren frames it in deeply personal terms. “There’s no evidence of disease—I’m in remission, and I still think about it every day,” said Dahlgren.
With CVC working lockstep with PICI, Dahlgren and Knudsen are working together to remove those barriers by building a system that does not just generate knowledge but delivers it. For Dahlgren, joining PICI is not a departure from her mission but an amplification of it. “I’ve always looked for the quickest path to these better treatments, and there’s just no doubt that under this new structure that we’ll be able to have a lot more impact.” For Knudsen, it is the continuation of a career spent bridging science and care. “It’s the businessperson in me always looking for how we go faster and farther and make it so that patients benefit more quickly.”
Dahlgren and Knudsen are betting on a future where cancer vaccines and the systems that support them transform not just how cancer is treated but how innovation itself happens. If they’re right, the question will be how quickly these breakthroughs can reach those who need them most.
BOX 1. The Rise of Personalized Cancer Vaccine
Personalized cancer vaccines are rapidly emerging as one of the most promising frontiers in oncology. Unlike traditional therapies, these vaccines are designed for each individual patient, using the unique mutations in their tumor to train the immune system to recognize and destroy cancer cells. Powered by advances in mRNA technology and genomic sequencing, this approach has shifted from theory to real clinical momentum in just a few years.
Early trial results are beginning to validate the strategy. In pancreatic cancer, one of the most difficult diseases to treat, a personalized mRNA vaccine developed by teams led by Vinod P. Balachandran, MD, and Benjamin D. Greenbaum, PhD, at Memorial Sloan Kettering Cancer Center triggered strong, lasting immune responses and extended survival in early-stage studies. In melanoma, combining a personalized vaccine with Keytruda reduced the risk of recurrence or death by 44% to 50%, advancing the approach into large Phase III trials.
Trials in lung, breast, and other tumors show that these vaccines are safe, feasible, and capable of generating strong T-cell responses. Increasingly, they are used in combination with checkpoint inhibitors, acting as a primer that enhances broader immune attack.
The pipeline is growing quickly. Dozens of personalized mRNA and DNA vaccines are now in development, with many expected to reach late-stage trials before 2030. Preventive versions, aimed at stopping cancer before it develops, are also beginning to enter human testing.
Investment is accelerating alongside the science. Pharmaceutical companies, biotech firms, and governments are committing billions to personalized vaccine platforms. In the United Kingdom, a partnership between the National Health Service and BioNTech aims to treat up to 10,000 patients with individualized vaccines by 2030.
Challenges remain, including small trial sizes, complex manufacturing, and the need for large-scale validation. Still, the trajectory is clear. Personalized cancer vaccines are moving steadily toward mainstream clinical use.
Jonathan D. Grinstein, PhD, North American editor for Inside Precision Medicine, investigates the most recent research and developments in a wide range of human healthcare topics and emerging trends, such as next-generation diagnostics, cell and gene therapy, and AI/ML for drug discovery. He is also the host of the Behind the Breakthroughs podcast, featuring people shaping the future of medicine. Jonathan earned his PhD in biomedical science from the University of California, San Diego, and a BA in neural science from New York University.
